×
Time:2024-01-13
Recently, NHU has secured approval for domestic drug registration of its API Coenzyme Q10, positioning the company as the first enterprise to receive such approval since the issuance of the National Medical Products Administration (NMPA)'s Announcement on Matters Related to Further Improving the Review, Approval, and Supervision of Drugs in 2019. This significant milestone indicates that our Coenzyme Q10 is at the forefront of the industry and paves the way for a new API market, presenting fresh opportunities for our development.
About Coenzyme Q10
Coenzyme Q10, a fat-soluble antioxidant, plays a crucial role in fortifying the myocardium, preventing heart aging, preventing and combating cancer, maintaining cardiovascular health, and enhancing overall vitality. The significant market demand for Coenzyme Q10 exists both domestically and internationally. The production of API Coenzyme Q10 necessitates stringent quality control and safety inspections, leading to rigorous requirements for production processes and product quality. NHU stands out as the inaugural company to receive such approval and recognition, demonstrating the company’s capability to produce high-quality API Coenzyme Q10 since the drug approval reform by the NMPA in 2019.
In its role as a guardian of nutrition and health, NHU is committed to the journey of open innovation. Starting from addressing future and potential market needs, we collaborate with academia and industry to delve into the cutting edges of chemical and biological science and technology and foster innovation and advancement, leading to the successful development of products like the Vitamin Series, Moxifloxacin Hydrochloride, and Taurine. NHU aims to create value for the entire industry and society, establishing a "Safety Moat" for human health.
On June 13, the 16th China Listed Company Investor Relations Forum, organized by Securities Times, was held in Yangzhou, Jiangsu. After self-nomination, professional screening, expert review, and regulatory review, NHU received the “Tianma Award for Investor Relations Management” in recognition of our strong corporate governance, high quality information disclosure, and excellent investor relations.
View details
On May 27, the 2025 Shaoxing " Enterprise Support Action" was launched. NHU was recognized as one of Shaoxing’s top 500 private enterprises and was also awarded top 10 in R&D investment and top 10 in exports. These honors highlight NHU’s strong capabilities in technological innovation and global reach. Rooted in Shaoxing and embracing a path toward greater "intelligence", we look forward to collaborating with more partners to create a high-quality future together.
View details
On April 18, the 2025 China Feed Industry Exhibition officially kicked off at the Qingdao International Convention and Exhibition Center.As a global innovator in animal nutrition, NHU put the spotlight on technological innovation, making a strong presence at the event with a diverse lineup of products and solutions. On site, NHU joined experts, scholars, and industry leaders in exploring cutting-edge trends and innovative technolgies of the field.
View details